Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): a randomized, multicenter, phase III clinical trial

References

• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study [published correction appears in Lancet. 2018 Jan 19]. Lancet. 2018;391(10127):1285–300. doi:10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Yewale V, Choudhury P, Thacker N. Influenza vaccines. IAP guide book on Immunization (Indian Academy of Pediatrics); 2009. Vol. 10, p. 123–30.
   Google Scholar
• Mathew JL. Influenza vaccination of children in India. Indian Pediatr. 2009;46:304–07.
   PubMed Web of Science ®Google Scholar
• Broor S, Parveen S, Bharaj P, Prasad VS, Srinivasulu KN, Sumanth KM, Kapoor SK, Fowler K, Sullender WM. A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS ONE. 2007;2:e491. doi:10.1371/journal.pone.0000491.
   PubMed Web of Science ®Google Scholar
• Balasubramanian S, Shah A, Pemde HK, Chatterjee P, Shivananda S, Guduru VK, Soans S, Shastri D, Kumar R. Indian academy of pediatrics (IAP) advisory committee on vaccines and immunization practices (ACVIP) recommended immunization schedule (2018-19) and update on immunization for children aged 0 through 18 years. Indian Pediatr. 2018;55(12):1066–74. doi:10.1007/s13312-018-1444-8.
   PubMed Web of Science ®Google Scholar
• Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012 March 30;11:1993–98. PMID:22226861. doi:10.1016/j.vaccine.2011.12.098.
   Google Scholar
• World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012–2013 northern hemisphere influenza season; 2012. [accessed 2020 April 1]. http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf?uaD1
   Google Scholar
• Sharma S, Singh VB, Kumar S, Prajapati V, Patel J, Vukkala R, Jangid SK, Sanmukhani J, Gupta G, Patel P, et al. Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II/III clinical trial. Hum Vaccin Immunother. 2018;14(6):1362–69. doi:10.1080/21645515.2018.1441654.
   PubMed Web of Science ®Google Scholar
• Influenza vaccine. Fluzone quadrivalent [package insert]. Swiftwater: Sanofi Pasteur; 2020.
   Google Scholar
• Influenza vaccine. Fluarix quadrivalent [package insert]. Germany: GlaxoSmithKline Biologicals; 2020.
   Google Scholar
• Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA. 2010;303(1):37–46. doi:10.1001/jama.2009.1911.
   PubMed Web of Science ®Google Scholar
• Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Sicilia JC, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: A phase III randomized controlled trial in children. J Infect Dis. 2013;208(4):544–53. doi:10.1093/infdis/jit263.
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207(12):1878–87. doi:10.1093/infdis/jit091.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee KY, Kim CS, Eun BW, Kim HM, Kim DH, Kim DH, Hong YJ, Choi YY, Jo DS, et al. Safety and immunogenicity of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean Children: a randomized, double-blinded, active-controlled phase III study. J Korean Med Sci. 2018;33:e100. doi:10.3346/jkms.2018.33.e100.
   PubMed Web of Science ®Google Scholar
• Kang JH, Oh CE, Lee J, Lee S-Y, Cha S-H, Kim DS, Kim -H-H, Lee J-H, Kim J-T, Ma S-H, et al. Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: A randomized, double-blinded, active-controlled, phase III study. J Korean Med Sci. 2011;26(11):1421‐1427. doi:10.3346/jkms.2011.26.11.1421.
   Web of Science ®Google Scholar
• US Food and Drug Administration Guidance for Industry. Clinical data needed to support the licensure of seasonal inactivated influenza vaccines; May 2007, (accessed 2020 Mar 28]. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf
   Google Scholar
• Jennings L, Huang QS, Barr I, Lee PI, Kim WJ, Buchy P, Sanicas M, Mungall BA, Chen J. Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region. Influenza Other Respir Viruses. 2018;12(3):383–411. Epub 2018 Mar 7. PMID: 29127742; PMCID: PMC5907823. doi:10.1111/irv.12522.
   PubMed Web of Science ®Google Scholar
• Mudhigeti N, Racherla RG, Mahalakshmi PA, Pamireddy ML, Nallapireddy U, Kante M, Kalawat U. A study of influenza 2017–2018 outbreak in Andhra Pradesh, India. Indian J Med Microbiol. 2018;36:526–31. doi:10.4103/ijmm.IJMM_18_272.
   PubMed Web of Science ®Google Scholar
• Khan UH, Mir MA, Ahmad F, Mir MH, Bali NK, Lal RB, Broor SS, Koul PA. An outbreak of influenza B in an isolated nomadic community in Jammu & Kashmir, India. Indian J Med Res. 2013;138:1012–15.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81–88. doi:10.4161/hv.8.1.17623.
   PubMed Web of Science ®Google Scholar